Skip to main content
SpringerLink
Log in

Eindrückliche Verbesserung des Überlebens beim metastasierten HER2-low-Mammakarzinom – Etablierung einer neuen Subgruppe?

Impressive improvements in survival for patients with HER2-low metastatic breast cancer—establishing a new subgroup?

  • Journal Club
  • Published:
Die Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Burris HA et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405

    Article  CAS  Google Scholar 

  2. Fehrenbacher L et al (2018) Abstract GS1-02: NSABP B‑47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Res 78:GS1–2

    Article  Google Scholar 

  3. Modi S et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9–20

    Article  CAS  Google Scholar 

  4. Bardia A et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529–1541

    Article  CAS  Google Scholar 

  5. Pervan M et al (2021) Deutliche Verbesserung des Gesamtüberlebens durch Sacituzumab-Govitecan beim metastasierten tripelnegativen Mammakarzinom. Onkologe 27:1131–1136

    Article  Google Scholar 

  6. Ogitani Y et al (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T‑DM1. Clin Cancer Res 22:5097–5108

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23583, Lübeck, Deutschland

    M. Pervan, H. Princk,  L. Hanker,  A. Rody,  N. Bündgen &  M. Banys-Paluchowski

Authors
  1. M. Pervan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Princk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Hanker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Rody
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Bündgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Banys-Paluchowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Pervan.

Ethics declarations

Interessenkonflikt

M. Pervan erhielt Travel Grants von Pfizer und IGEA Medical. M. Banys-Paluchowski erhielt Honorare für Vorträge und beratende Tätigkeiten von: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, AstraZeneca, Amgen, Samsung, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Pintuition, Pierre Fabre sowie Studienunterstützung von: EndoMag, Mammotome, MeritMedical, Gilead. H. Princk erhielt Honorare für Vorträge und Travel Grants von Astra Zeneca, Roche, Daiichy Sankyo, Pfizer, Novartis, Pierre Fabre, L. Hanker erhielt Honorare von Amgen, Astra Zeneca, Clovis, GSK, Intuitive Surgery, Janssen, Novartis, Pfizer, Pharma Mar, Roche, Tesaro, A. Rody und N. Bündgen geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pervan, M., Princk, H., Hanker, L. et al. Eindrückliche Verbesserung des Überlebens beim metastasierten HER2-low-Mammakarzinom – Etablierung einer neuen Subgruppe?. Onkologie 29, 157–159 (2023). https://doi.org/10.1007/s00761-022-01276-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-022-01276-8

Search

Navigation